Zacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million

Equities research analysts predict that CymaBay Therapeutics Inc (NASDAQ:CBAY) will report sales of $6.75 million for the current quarter, Zacks reports. Two analysts have provided estimates for CymaBay Therapeutics’ earnings, with the highest sales estimate coming in at $10.00 million and the lowest estimate coming in at $3.50 million. The firm is expected to announce its next quarterly earnings report on Thursday, March 22nd.

On average, analysts expect that CymaBay Therapeutics will report full year sales of $6.75 million for the current fiscal year, with estimates ranging from $4.80 million to $14.79 million. For the next year, analysts expect that the company will report sales of $0.00 per share. Zacks’ sales calculations are an average based on a survey of research firms that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same period in the previous year, the company earned ($0.25) EPS.

A number of analysts have weighed in on the stock. Oppenheimer set a $15.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Monday, October 30th. Piper Jaffray Companies reissued a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Friday, October 27th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Leerink Swann reissued a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. CymaBay Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.50.

In other news, SVP Charles Mcwherter bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $8.67 per share, for a total transaction of $43,350.00. Following the acquisition, the senior vice president now directly owns 10,300 shares in the company, valued at $89,301. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kurt Von Emster sold 173,192 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $9.41, for a total value of $1,629,736.72. Following the completion of the transaction, the director now owns 90,000 shares in the company, valued at $846,900. The disclosure for this sale can be found here. Insiders have sold a total of 300,449 shares of company stock worth $2,797,929 over the last 90 days. Company insiders own 15.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of CBAY. Bank of New York Mellon Corp lifted its holdings in shares of CymaBay Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 140 shares in the last quarter. Marshall Wace North America L.P. bought a new position in shares of CymaBay Therapeutics in the 2nd quarter worth $242,000. Ardsley Advisory Partners lifted its holdings in shares of CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth $404,000. Finally, Crestline Management LP bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth $841,000. Institutional investors own 69.12% of the company’s stock.

Shares of CymaBay Therapeutics (NASDAQ CBAY) opened at $9.90 on Friday. The firm has a market cap of $434.25, a P/E ratio of -9.80 and a beta of 1.82. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics has a 52-week low of $1.46 and a 52-week high of $10.00.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/zacks-analysts-anticipate-cymabay-therapeutics-inc-cbay-will-announce-quarterly-sales-of-6-75-million.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply